SEC Tracker
Get the app

Cerus CERS

Cerus announced third quarter 2026 financial results

Item 2.02 Reports results

Form
8-K
Filed
Importance
Major
  1. Third quarter 2026 total revenue of $64.0 million
  2. Product revenue of $57.7 million, up 10% year-over-year
  3. Positive topline Phase 3 RedeS results for INTERCEPT Blood System
  4. Net loss of $0.6 million for the third quarter

Written from the 8-K on EDGAR. Check the filing before you rely on it.

Open in the appGet the appView on EDGAR

Get an email when Cerus files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

The reading, claim by claim

0 of 3 claims matched the filing text.

Not found in the filing text

  • For the quarter ended June 30, 2026, CERUS CORP reported revenue of $57.4 million and a net income of -$2.9 million.
  • The company's operating margin was -3.2% and net margin was -5.1% for the quarter.
  • Revenue increased by 9.5% compared to the same period a year earlier.

Similar companies

Companies of similar size in SIC 3841 and related industry codes: the same peer list as the financial tables.

  1. SANUWAVE Health SNWV public float $233M, Jun 30, 2025
  2. Electromed ELMD public float $224M, Dec 31, 2025
  3. Tactile Systems Technology TCMD public float $223M, Jun 30, 2025
  4. Orasure Technologies OSUR public float $218M, Jun 30, 2025
  5. Heartflow HTFL